Condition: Polypoidal Choroidal Vasculopathy · Polypoidal Choroidal Vasculopathy (PCV) · Sponsor: Yeungnam University College of Medicine
The purpose of this study is to evaluate the efficacy and safety of the aflibercept 8 mg used in a personalized regimen, with flexible loading dose and treatment intervals from 8 to 24 weeks in eyes with treatment-naive PCV.
This description comes directly from the study's public registry record.
Sohee Shin · 82-53-620-3440 · ey005@ymc.yu.ac.kr
Always discuss trial participation with your own doctor first.
| Yeungnam University Hospital | Daegu, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07389980